Janssen’s COVID-19 vaccine received a WHO Emergency Use Listing (EUL) on 12 March and is relying on a global supply network to produce the vaccine. The latest site for production, Aspen Pharmacare in Gqeberha, South Africa, was approved by the WHO on 29 June. Deliveries of the vaccine are expected to begin later in the 3rd quarter of 2021, with allocations to be determined by the Africa CDC.
The agreement comes as the African continent faces the steepest surge in COVID-19 cases yet, and vaccine supply challenges have left many countries with large unvaccinated populations.
In addition to its role in this partnership, UNICEF is also a key implementing partner for the COVAX Facility led by Gavi, the Vaccine Alliance, WHO and CEPI. Under this initiative, UNICEF has contributed to the delivery of more than 100 million doses to 135 countries. UNICEF’s role procuring and delivering COVID-19 vaccines on behalf of AVAT will complement and supplement the shared COVAX goal of ensuring equitable access to quality-assured COVID-19 vaccines.
“Vaccinating the world against COVID-19, as the virus continues to spread and mutate, is one of the largest and most complex collective health undertakings the world has ever seen, and we need all hands on deck,” said Fore. “In the race to defeat this virus, equity is not a ‘nice to have’ — it’s an absolute necessity. This pandemic has cost everyone something, and some people everything. Only together can we bring the suffering to an end.”
